

THE GROWTH ENTERPRISE MARKET (GEM)**COMPANY INFORMATION SHEET**Case Number: 20121130-F08122-0002

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: LifeTech Scientific Corporation 先健科技公司Stock code (ordinary shares): 8122

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 22 January 2013.

A. GeneralPlace of incorporation: Cayman IslandsDate of initial listing on GEM: November 10, 2011Name of Sponsor(s): Piper Jaffray Asia Limited

Names of directors:
(please distinguish the status of the directors
- Executive, Non-Executive or Independent
Non-Executive)

XIE Yuehui (Executive Director)
ZHAO Yiwei Michael (Executive Director)
WU Jianhui (Non-Executive Director)
LIANG Hsien Tse Joseph (Independent Non-Executive Director)
ZHANG Xingdong (Independent Non-Executive Director)
ZHOU Gengshen (Independent Non-Executive Director)

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	<ol style="list-style-type: none"> 1. Orchid Asia III, L.P.; 19.73% of Company's shareholding (beneficial owner) 2. OAIM Holdings, L.P.; 19.73% of Company's shareholding (interest in a controlled corporation, Orchid Asia III, L.P.) 3. Orchid Asia Group Management, Limited; 19.73% of Company's shareholding (interest in a controlled corporation, Orchid Asia III, L.P.) 4. Orchid Asia Group Limited; 19.73% of Company's shareholding (interest in a controlled corporation, Orchid Asia III, L.P.) 5. YM Investment Limited; 19.73% of Company's shareholding (interest in two controlled corporations, Orchid Asia Co-Investment Limited and Orchid Asia Group Limited) 6. ManageCorp Limited; 19.73% of Company's shareholding (trustee of The Li 2007 Family Trust) 7. Ms. Lam Lai Ming; 19.73% of Company's shareholding (founder of The Li 2007 Family Trust) 8. Mr. Gabriel Li; 19.73% of Company's shareholding (founder of The Li 2007 Family Trust) 9. Xianjian Advanced Technology Limited; 20.31% of Company's shareholding (beneficial owner) 10. Mr. Xie Yuehui; 20.31% of Company's shareholding (interest in a controlled corporation, Xianjian Advanced Technology Limited) 11. GE Asia Pacific Investments Ltd.; 17.58% of Company's shareholding (beneficial owner) 12. Mr. Wu Jianhui; 17.58% of Company's shareholding (interest in a controlled corporation, GE Asia Pacific Investments Ltd.)
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	Nil
Financial year end date:	December 31
Registered address:	PO Box 309, Uglan House, Grand Cayman, KY1-1104, Cayman Islands
Head office and principal place of business:	Cybio Electronic Building, Langshan 2nd Street, North Area of High-tech Park, Nanshan District, Shenzhen 518057, PRC
Web-site address (if applicable):	www.lifetechmed.com
Share registrar:	Tricor Investor Services Limited 26/F, Tesbury Centre, 28 Queen's Road East, Wanchai Hong Kong
Auditors:	Deloitte Touche Tohmatsu Certified Public Accountants 35/F One Pacific Place, 88 Queensway, Hong Kong

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

B. Business activities

The Company and its subsidiaries (the “Group”) are a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Group believes that it offers one of the broadest product ranges of congenital heart defect occluders through its three generations of occluder series HeartR, Cera and CeraFlex. It also offers six other types of minimally invasive implants and devices, including its proprietary Aegisy vena cava filters, Ankura stent grafts, Green Arrow/Blue Arrow/Red Arrow balloon catheters, Cera and CeraFlex vascular plugs, Supporter coronary stents and the PerMed bovine heart valve. In addition, the Group also manufactures and sells nine types of associated delivery and supporting devices, including its FuStar steerable introducer.

C. Ordinary shares

Number of ordinary shares in issue: 500,000,000

Par value of ordinary shares in issue: US\$0.00001

Board lot size (in number of shares): 2,000

Name of other stock exchange(s) on which ordinary shares are also listed: N/A

D. Warrants

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Conversion ratio: N/A
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

E. Other securities

Not applicable

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Responsibility statement

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

XIE Yuehui
Executive Director

ZHAO Yiwei Michael
Executive Director

WU Jianhui
Non-Executive Director

LIANG Hsien Tse Joseph
Independent Non-Executive Director

ZHANG Xingdong
Independent Non-Executive Director

ZHOU Gengshen
Independent Non-Executive Director

NOTES

- (1) *This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.*
- (2) *Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.*
- (3) *Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.*